SAS Output

24-MAR-2017 18:10

LUNG ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1400-SCCA,Adv, Biomarker Master 1 Y 1 Specimen Submission   1199 567 190 77 31 6 07/08/2014 433 214
            1199 567 190 77 31 6      
 
    2 Y 17 S1400G   5 5 5 5 3 0      
        2 S1400A   160 0 0 0 0 0 07/08/2014    
        3 S1400B   54 24 5 0 0 0      
        4 S1400C   88 16 0 0 0 0      
        5 S1400D   93 35 2 0 0 0      
        6 S1400E   16 0 0 0 0 0      
        7 S1400I   485 364 171 68 27 7      
            901 444 183 73 30 7      
 
    3 P 10 S1400I   6 6 6 1 0 0      
        18 S1400G   3 3 3 3 3 2      
        8 S1400B   1 1 0 0 0 0 07/08/2014    
            10 10 9 4 3 2      
 
  S1400A-Non-Match: MEDI4736 1 N 1 MEDI4736 140 78 0 0 0 0 0 07/31/2014 4 5
        2 Docetaxel   38 0 0 0 0 0      
            116 0 0 0 0 0      
 
    2 Y 3 MEDI4736 140 2 2 1 1 0 0 07/31/2014    
            2 2 1 1 0 0      
 
  S1400G-HRRD: Talazoparib (BMN 673) 1 Y 1 Talazoparib (BMN 673) 60 1 1 1 1 1 0 03/03/2017 406 192
            1 1 1 1 1 0      
 
  S1400I-Non-Match: Nivo + Ipi vs Nivo 1 Y 1 Nivolumab + Ipilimumab 350 89 78 37 12 2 1 12/29/2015 436 218
        2 Nivolumab   89 81 33 12 5 0      
            178 159 70 24 7 1      
 
  S1403-Adv,EGFR-mt,Afatinib+/-Cetuximab 1 Y 1 AFATINIB + CETUXIMAB 605 45 28 11 5 2 0 05/07/2015 221 88
        2 AFATINIB   48 28 15 9 0 0      
            93 56 26 14 2 0      
 
  S1507-NSCLC, Adv, Kras Mut, Trametinib + Docetaxel 1 Y 1 Trametinib + Docetaxel 53 20 20 20 13 4 0 10/05/2016 161 76
            20 20 20 13 4 0      
 
  8811-NSCLC, Stage III,ChemoRT+ABT-888 1 Y 5 RT+Pac+Carbo+blinded drug 132 7 7 7 5 3 1 01/24/2013 77 27
        6 RT+Pac+Carbo+blinded drug   7 7 6 4 1 0      
            14 14 13 9 4 1      
 
    2 Y 8 Pac + Carbo + blinded drug 132 3 3 3 3 2 0 01/24/2013    
            3 3 3 3 2 0      
 
Yes A081105-ALCHEMIST1, EGFR mut, Erlotinib 1 E Total Registrations   16 8 4 3 1 0 04/01/2015   242
            16 8 4 3 1 0      
 
  A151216-ALCHEMIST0 - screening 1 E Total Registrations   264 159 97 59 28 6 12/16/2014 455 244
            264 159 97 59 28 6      
 
  C140503-NSCL, Lobect v Sublobar resect 1 E Total Registrations   17 4 1 0 0 0 07/02/2008 100 57
            17 4 1 0 0 0      
 
    2 E Total Registrations   27 3 1 0 0 0 07/02/2008    
            27 3 1 0 0 0      
 
  C30610-SCLC, Thoracic RT 1 E Total Registrations   50 0 0 0 0 0 05/14/2008 237 111
            50 0 0 0 0 0      
 
  E4512-ALCHEMIST2, ALK mut, Crizotinib 1 E Total Registrations   3 1 0 0 0 0 02/29/2016 461 245
            3 1 0 0 0 0      
 
  NRGCC003-SCLC, PCI or HA-PCI 1 E Total Registrations   1 1 1 0 0 0 10/20/2016 282 117
            1 1 1 0 0 0      
 
    2 E Total Registrations   1 1 1 0 0 0 10/20/2016    
            1 1 1 0 0 0      
 
  R1306-NSCLC,Adv,ALK/EGFR,TargetAgents 1 E Total Registrations   8 0 0 0 0 0 03/12/2014 157 67
            8 0 0 0 0 0      
 
No A151216-ALCHEMIST0 - screening 0 E Total Registrations   270 160 96 58 28 7 12/16/2014 455 244
            270 160 96 58 28 7      
 
  C30607-NSCL,Adv Main Sunitinib v Placbo 1 E Total Registrations   2 0 0 0 0 0 09/25/2013    
            2 0 0 0 0 0      
 
  EA5142-ALCHEMIST3, Non-match, Nivolumab 1 E Total Registrations   8 8 7 2 1 1 08/03/2016 426 217
            8 8 7 2 1 1